Novel Immunotherapy Approaches Targeting TIGIT: Updates and Perspectives for the Oncology Care Team
  • CME
  • CE

Diwakar Davar, MD, and Jyoti D. Patel, MD, discuss the role of and rationale for targeting TIGIT, as well as current data and emerging therapies.
person default
Diwakar Davar, MD
person default
Jyoti D. Patel, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: April 27, 2022 Expiration: April 26, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the mechanism of action of TIGIT-targeted therapies and the rationale for combining with other cancer treatment options
  • Evaluate the available clinical trial evidence on anti-TIGIT immunotherapies across tumor types
  • Implement supportive management strategies for identified adverse events associated with anti-TIGIT immunotherapies and combinations
  • Identify patients eligible for enrollment on clinical trials investigating anti-TIGIT therapies alone or in combination with other immunotherapies

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech, a member of the Roche Group

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Diwakar Davar, MD

Assistant Professor
Melanoma and Phase I Therapeutics
Division of Hematology/Oncology
Department of Medicine
University of Pittsburgh Hillman Cancer Center
Pittsburgh, Pennsylvania

Diwakar Davar, MD, has disclosed that he has received funds for research support from Arcus, CellSight Technologies, Checkmate Pharmaceuticals, GlaxoSmithKline/Tesaro, Immunocore, and Merck and consulting fees from Checkmate Pharmaceuticals, Finch, Shionogi, and Vedanta.
Jyoti D. Patel, MD

Professor of Medicine
Division of Hematology and Oncology
Medical Director for Thoracic Oncology
Assistant Director for Clinical Research
Associate Vice Chair of Clinical Research
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Jyoti D. Patel, MD, has disclosed that she has received funds for research support from AstraZeneca and consulting fees from AbbVie and Takeda.

Staff

Kelly Brandt, PharmD
Kelly G. Brandt, PharmD, BCOP, BCPS, has no relevant conflicts of interest to report.
Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz has no relevant conflicts of interest to report.
Kristi Kay Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Orbaugh, MSN, NP, AOCNP has disclosed that she has served as a speaker for AstraZeneca, Bristol-Myers Squibb, DSI, Gilead Sciences, Lilly, Morphosys, Pfizer, Regeneron, and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncologists, nurse practitioners, physician assistants, nurses, pharmacists, oncology multidisciplinary teams, and other healthcare professionals involved in the treatment of patients with solid tumors.

Goal

The goal of this program is to improve the knowledge, confidence, and competence of learners in understanding and applying the latest science and clinical trial data on current and emerging anti-TIGIT immunotherapies across tumor types to clinical practice.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-121-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 27, 2022, through April 26, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable clinical resource with practical guidance on how to talk with your transgender patients about gender identity, including related terminology, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 30, 2022

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy into community care

Jesús G. Berdeja, MD Caron A. Jacobson, MD Released: June 30, 2022

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 28, 2022

Update of ATEZO-BRAIN trial evaluating atezolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC with untreated brain metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings